CDx Diagnostics
6
1
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
33.3%
2 terminated/withdrawn out of 6 trials
60.0%
-26.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Clinical Utility of WATS3D: A 5-Year Prospective Study
Role: lead
The WATS3D (Wide Area Transepithelial Sample Biopsy With 3-Dimensional Computer-Assisted Analysis) U.S. Registry
Role: lead
WATS3D for the Detection of Esophageal Dysplasia
Role: lead
Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
Role: lead
CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions
Role: lead
The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy
Role: lead
All 6 trials loaded